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Diffusion weightedAbstract Aim of the work: To assess the utility of hepatic ADC of diffusion weighted MRI in the
diagnosis of liver ﬁbrosis in chronic hepatitis C patients and to evaluate its relationship with both
the stage of liver ﬁbrosis and grade of necro-inﬂammation.
Subjects and methods: Forty patients with chronic viral hepatitis C and 30 healthy control group
were examined by 1.5 T MRI scanner using DWI at b-values of 100, 400 and 800 s/mm2. The mean
ADC values of both patients and the control group were correlated to biopsy ﬁndings and graded
according to METAVIR scoring system.
Results: The mean ADC values of the liver at all b-values were statistically signiﬁcantly lower in
the study group than those of the control group. A strong negative correlation was found between
the mean ADC value and the stage of ﬁbrosis. No signiﬁcant correlation was found between the
mean ADC value and the grade of necroinﬂammation.
Conclusion: The ADC value of diffusion weighted MRI can be used to distinguish between liver
parenchyma of patients with chronic viral hepatitis C and healthy subjects and it is useful for esti-
mation of the stage of liver ﬁbrosis but not valuable in estimation of the grade of necro-inﬂamma-
tion.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Egypt has the highest HCV prevalence in the world with esti-
mated prevalence in the 15–59 years age group to be 14.7%.
This unparalleled level of exposure to this infection appears
to reﬂect a national level epidemic (1).
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chronic hepatitis C (2). The progression of hepatic ﬁbrosis is
slow, with progression from stage 0 (no ﬁbrosis) to stage 4 (cir-
rhosis). However, it is recognized that some patients do not
progress while others rapidly develop signiﬁcant ﬁbrosis (3).
In the early stages, the progression of ﬁbrosis can be pre-
vented or reversed by antiﬁbrotic treatment or by eliminating
the cause. Therefore, diagnosis of ﬁbrosis in the initial stages
is critically important for the prognosis of the disease (4).
Staging of liver ﬁbrosis by liver biopsy represents the gold
standard for prognostic assessment and indication to initiate
antiviral therapy (5). Liver biopsy, however, has a number of
limitations, being invasive, costly, difﬁcult to standardize,
and disliked by many patients (6).
Several non-invasive radiological and non-radiological
techniques are available for assessment of liver ﬁbrosis and cir-
rhosis, each with its beneﬁts and limitations (7).
Studies using CT, ultrasound, and MRI have identiﬁed
reduction in the size of the right lobe of the liver with a relative
enlargement of the left and caudate lobes as reliable markers of
cirrhosis (7).
The conventional deﬁnition of the ﬁbrosis stage of the liver
based on an evaluation of ultrasound factors is deﬁcient and
lacks precision and consistency (8). Doppler US can provide
important information on the hemodynamics of the portal
venous system, the hepatic artery, and the hepatic veins. Sev-
eral limitations of Doppler assessment exist, including the var-
iability of the portal ﬂow velocity in healthy and cirrhotic
patients, inter-observer variability, differences in methodology
and equipment used, and errors in Doppler sampling (9).
CT and conventional MRI showed limited sensitivity in
early ﬁbrosis. Diagnosis with double contrast material-
enhanced MR imaging can detect advanced hepatic ﬁbrosis
(10).
Fibroscan and aspartate aminotransferase/platelet ratio in-
dex (APRI) are promising non-invasive alternatives to liver
biopsy for detecting hepatic ﬁbrosis, however are not useful
tools in early stages of ﬁbrosis (11).
In liver ﬁbrosis, extracellular collagen ﬁbers, glycosamino-
glycans and proteoglycans may inhibit molecular diffusion of
water, which suggest that diffusion weighted imaging (DWI)
can be an effective method for the evaluation of ﬁbrosis (4).
Several studies showed that ADC values of the liver are low-
er in patients with liver cirrhosis compared with controls. How-
ever limited research on the utility of DWI in staging of both
ﬁbrosis and inﬂammation together could be found (12–15).
The purpose of this study was to assess the utility of hepatic
ADC of diffusion weighted MRI in the diagnosis of liver
ﬁbrosis in chronic hepatitis C patients and to evaluate its rela-
tionship with both the stage of liver ﬁbrosis and grade of ne-
cro-inﬂammation.2. Patients and methods
This prospective study was performed over a period of one
year, between November 2012 and November 2013. Forty pa-
tients with viral hepatitis C (28 males and 12 females), with
their age range between 27 and 68 years with a mean age of
46 years were included in the study. All were referred from
the Hepatology outpatient clinic at our institution. Thirty
(22 males and 8 females) liver disease free patients, werescanned as a control group for the study. Patients with hepa-
titis C were diagnosed on the basis of clinical history, results
of liver function tests, results of PCR for HCV, and percutane-
ous liver biopsy. Patients with focal liver disease, those with
co-infection by HBV, patients with diffuse liver disease (e.g.
fatty liver and Wilson’s disease), and lastly those with contra-
indications to MRI study or liver biopsy were excluded from
the study.
Control subjects included in the study are those without
history of acute or chronic liver disease, with normal liver
function tests and negative PCR, exclusion criteria of the con-
trol subjects included patients refusing imaging by MRI after
explanation of the nature of the examination.
2.1. Histopathology
A blinded percutaneous liver biopsy was performed in patients
with chronic viral hepatitis C by an experienced hepatologist at
least 10 days before the MRI, to avoid artifacts related to early
post-biopsy changes, but no longer than 2 months prior to it,
to avoid the upstaging of the disease. The biopsy specimens
were examined by an experienced pathologist to evaluate the
stages of liver ﬁbrosis and grades of necro-inﬂammatory
changes of the liver in chronic viral hepatitis C using the
METAVIR (16) scoring system, which assesses histologic le-
sion in hepatitis C using two separate scores, one for ﬁbrosis
classiﬁcation into the following stages, F0 = no ﬁbrosis,
F1 = portal ﬁbrosis without septae, F2 = few septae,
F3 = bridging ﬁbrosis without cirrhosis and F4 = cirrhosis
with architectural distortion. The second score classiﬁes the ne-
cro-inﬂammatory changes (i.e. histological activity) into the
following grades, A0 = no activity, A1 = mild activity,
A2 = moderate activity and A3 = severe activity.
2.2. MRI examination
Diffusion weighted MRI sequences were included in the liver
scanning protocol for all the patients and the control group
using Signa Excite 1.5 T system (GE healthcare, Milwaukee,
WI, USA), the phased array body coil was placed around
the upper abdomen to allow for proper coverage of the liver
anatomy. Diffusion weighted images were acquired in the
transverse plane using single-shot echo-planar spin-echo
sequences obtained when the patients and control groups were
breathing normally using the following parameters: TR,
4500–6000, TE, 80–120, FOV = 32–40 cm, matrix size:
192–256, slice thickness: 6 mm, number of signal averaged: 2,
diffusion gradient encoding in 3 orthogonal directions at
b-values 100, 400 and 800 s/mm2, representing low, intermedi-
ate and high b-values.
2.3. Post-processing of ADC maps
It was done by a radiologist who was blinded to the histolog-
ical results and clinical history of both patients and control
groups, post-processing was performed using the standard
software supplied on the machine console to obtain ADC val-
ues and maps for each b-value.
The ADC values for the different b-values were obtained by
placing 4 regions of interest (ROIs) on the liver at the lateral
and medial segments of the left lobe and the anterior and
Fig. 1 Box plot showing the relationship between the mean
ADC values of the liver in the control group and the different
stages of ﬁbrosis in the patient group.
Table 2 Distributions of the hepatic mean ADC (value
·103 mm2/s) against necro-inﬂammatory grades in the patient
group.
Patients (n= 40) b-100 s/mm2 b-400 s/mm2 b-800 s/mm2
A1 (n= 13) 2.03 ± 0.3 1.78 ± 0.28 1.1 ± 0.47
A2 (n= 11) 2.09 ± 0.28 1.81 ± 0.3 1.17 ± 0.43
A3 (n= 16) 1.96 ± 0.32 1.75 ± 0.27 1.09 ± 0.48
Pearson correlation 0.117 0.051 0.017
p Value* 0.474 0.756 0.918
* p Value <0.05 is statistically signiﬁcant.
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between 1 and 2 cm2. Vascular structures and areas showing
motion artifacts were avoided and ROIs were placed far away
from them, the ﬁnal ADC value was the average of the 4 mea-
sured values for each b-value.
2.4. Statistical data analysis
Mann–Whitney U test was used to compare between the mean
ADC values of the control group and patient groups at the dif-
ferent b-values and to compare between the mean ADC values
of the patients with different stages of ﬁbrosis at the different
b-values, a conﬁdence interval of 95% was used and a p-value
<0.05 was considered statistically signiﬁcant. The correlation
between the stages of ﬁbrosis and the mean ADC values of the
patients and between the different grades of necro-inﬂamma-
tory changes and the mean ADC values of their patients was
determined using the Pearson correlation coefﬁcient test.
Statistical analysis software used was Minitab Ver.16 (Minitab
Inc., USA).
2.5. Ethical consideration
The study protocol was approved by the local ethics Commit-
tee at our institution and an informed consent was taken from
all participants.
3. Results
The mean ADC values of the liver (at b-value, 100, 400 and
800 s/mm2), were statistically signiﬁcantly lower in the study
group (n= 40) than the mean ADC value in the control group
(n= 30) with 0.05 (0.0001–0.03) and as the stage of ﬁbrosis
increased in the study group the mean ADC values decreased
(Pearson correlation = 0.984, p= 0.016 denoting a strong
negative correlation) (Table 1 and Fig. 1). A statistically
signiﬁcant difference of the mean ADC values, at all b-values,
was found between stages F1–F2, F1–F3, F1–F4, F2–F3 and
F2–F4 with p< 0.05 (0.0001–0.03). On the other hand, the
difference of the mean ADC values, at all b-values, between
F3 stage and F4 stage was statistically insigniﬁcant with a
p= 0.459 at b-100 s/mm2, p= 0.592 at b-400 s/mm2 and
p= 0.2818 at b-800 s/mm2.
Statistical analysis revealed no signiﬁcant correlation
between the mean ADC value (at b-value, 100, 400 and
800 s/mm2) and the grades of necro-inﬂammation of
METAVIR scoring system (Table 2).Table 1 Distribution of the mean hepatic ADC (value
·103 mm2/s) stratiﬁed by ﬁbrosis stages in the control and
patient groups.
b-100 s/mm2 b-400 s/mm2 b-800 s/mm2
Control (n= 30) 2.41 ± 0.26 2.17 ± 0.18 1.85 ± 0.12
F1 (n= 12) 2.06 ± 0.29 1.8 ± 0.2 1.6 ± 0.1
F2 (n= 12) 1.8 ± 0.3 1.6 ± 0.18 1.3 ± 0.06
F3 (n= 13) 1.45 ± 0.17 1.34 ± 0.24 0.91 ± 0.1
F4 (n= 3) 1.31 ± 0.24 1.02 ± 0.52 0.83 ± 0.084. Discussion
Despite the fact that liver ﬁbrosis is among the major causes of
life threatening complications including portal hypertension
and liver dysfunction, it is treatable when diagnosed early
(Figs. 2 and 3).
Based on this knowledge, it is clinically important to diag-
nose patients with chronic liver disease and follow them up
closely.
DWI is one of the imaging approaches that has been
recently studied for its utility in evaluation of liver ﬁbrosis
and to a relatively lesser extent in the evaluation of associated
necro-inﬂammatory changes. Its major advantage is it is a non-
invasive technique.
In our study 40 patients with chronic viral hepatitis C and
30 control healthy subjects were included in the study and
examined for ADC value of DW MRI with different b-values
(100, 400 and 800 s/mm2) which represent low, intermediate
and high values. It was found that the mean ADC values of pa-
tients with liver ﬁbrosis were statistically signiﬁcantly lower
than those of normal control subjects. Also, it was found that
the mean ADC value decreases when using a high b-value.
These ﬁndings are in concordance with most of the previous
studies (13,14,17,18), that showed the same results, yielding
DWI as a useful tool in differentiating healthy patients from
those with ﬁbrosis and cirrhosis and that using different
b-values affect the ADC values.
Fig. 2 (a–f) Control subject, a healthy female aged 34 years with normal liver function tests and negative testing for HCV. (a, c and e)
Diffusion weighted images of the liver at b-100, 400 and 800 s/mm2 respectively showing the 4 ROIs placed at the lateral and medial
segments of the left lobe and the anterior and posterior segments of the right lobe. (b, d and f) Apparent diffusion coefﬁcient maps for the
same control subject at b-100, 400 and 800 s/mm2 respectively showing the corresponding 4 ROIs with average ADC values of 3.94 · 103,
2.78 · 103 and 1.86 · 103 mm2/s.
670 M.A. Amin et al.Koinuma et al. (19) recommended using of multiple
b-values (low and high) which enabled more precise calculation
of ADC with less perfusion contamination. Moreover, Giro-
metti et al. (20) have found that in the assessment of hepatic
ﬁbrosis, there may be an advantage to calculate ADC values
using an intermediate b-value of 400 s/mm2 compared with a
high b-value of 800 s/mm2 and this was done in our study.
In our study it was found that a strong negative correlation
existed between the mean ADC values and the stage of ﬁbrosis,i.e. the higher the grade of ﬁbrosis the lower is the mean ADC
value of the liver. This ﬁnding was in agreement with
Sandrasegaran et al. (14), Taouli et al. (13), Bakan et al. (4)
and Koinuma et al. (19), who reported a moderate negative
correlation between the ADC values and stages of liver ﬁbro-
sis. However Boulanger et al. (12) could not ﬁnd a difference
between ADC values and ﬁbrosis scores in 18 patients with
hepatitis C and 10 healthy volunteers. This difference between
their results and ours may be attributed to their use of smaller
Fig. 3 (a–f) Patient with stage F3 ﬁbrosis, a female aged 42 years with mildly abnormal liver function tests and positive anti-HCV
antibodies with moderate viral load on PCR (14 · 103 IU/ml). (a, c and e) Diffusion weighted images of the liver at b-100, 400 and
800 s/mm2 respectively showing the 4 ROIs placed at the lateral and medial segments of the left lobe and the anterior and posterior
segments of the right lobe. (b, d and f) Apparent diffusion coefﬁcient maps for the same patient at b-100, 400 and 800 s/mm2 respectively
showing the corresponding 4 ROIs with average ADC values of 1.82 · 103, 1.68 · 103 and 1.12 · 103 mm2/s.
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patients and using a different pathologic scoring system (Ishak
(21) scoring system).
In our study, there was a statistically signiﬁcant difference
between the mean ADC values for F1 and F2 stages, F1 and
F3 stages, F1 and F4 stages, F2 and F3 and F2 and F4 ﬁbrosis
stages, at all b-values used, with p values <0.05. On the other
hand no statistically signiﬁcant difference was found between
the mean ADC values of patients with F3 and F4 stages. These
results are in agreement with those of Bakan et al. (4) who
found that, there were statistically signiﬁcant differences inmean ADC values between stages F0 and F2, stages F0 and
F3, stages F0 and F4, stages F1 and F3 and stages F2 and
F4, however, there were no statistically signiﬁcant differences
in ADC values between stages F0 and F1 and stages F1 and
F2. This difference between our ﬁndings and theirs may be
attributed to that there were no patients with F0 stage in our
study.
In the present study, in addition to examining the relation-
ship between the mean ADC values and ﬁbrosis stage, we
also assessed the relationship between the ADC value and
grades of necro-inﬂammation where no statistically signiﬁcant
672 M.A. Amin et al.correlation between the ADC values (b-100, b-400 and
b-800 s/mm2) and the grades of necro-inﬂammation was
found. These results were in agreement with Koinuma et al.
(19) who in their study evaluated a population of 163 patients
using a b-value of 128 s/mm2. Their results showed a negative
correlation between the hepatic ADC and ﬁbrosis scores but
no correlation between ADC and inﬂammation grade.
Boulanger et al. (12) did not ﬁnd any statistically signiﬁcant
relationship between ADC value and histological activity in-
dex (HAI) scores, while, Taouli et al. (13) found a weak nega-
tive correlation between the ADC and grade of inﬂammation.
In a recent study by Onur et al. (15) using b-values of 100,
600 and 1000 s/mm2, they found no signiﬁcant correlation
between the ADC value and the necro-inﬂammatory changes
of the liver, a ﬁnding which is in agreement with our results
using b-values of 100, 400 and 800 s/mm2.
Finally, in comparison with different published studies, few
points of difference were found including, the short time of
delay between the biopsy and MRI study (10 days to
2 months) to avoid upstaging of the disease, choosing one
group of patients in the study i.e. chronic hepatitis C patients,
investigating the usefulness of ADC value of DWI MRI in
both the estimation of the stages of liver ﬁbrosis and the grade
of necro-inﬂammation, using different b-values (100, 400 and
800 s/mm2), and lastly the use of METAVIR (16) scoring sys-
tem which is one of the most reliable scoring systems available.
Our study has some limitations, ﬁrst we are reporting our
initial experience at our institution, second the small number
of patients included in the study and lastly the absence of
patients with stage F0 in the study.
In conclusion, based on the ﬁndings of the study, the liver
mean ADC value of diffusion weighted MRI can be used to
distinguish between the liver parenchyma of normal healthy
patients and those with chronic viral hepatitis C and it is useful
for an estimation of the stage of liver ﬁbrosis, on the other
hand, it is not valuable in the estimation of the grade of
necro-inﬂammation.
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